PATENT CLAIM ANALYSIS

Application Number: 15976512
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "133100"]

Abstract:
This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.

Claim (Index 1):
A method for treating or inhibiting a thrombin-mediated thrombosis or embolism, comprising administering to a patient in need thereof an antibody molecule that specifically binds to the exosite 1 region of thrombin and comprises an HCDR1 having the amino acid sequence of SEQ ID NO: 3, an HCDR2 having the amino acid sequence of SEQ ID NO: 4, and an HCDR3 having the amino acid sequence of SEQ ID NO: 5, and a VL domain comprising the amino acid sequence of SEQ ID NO: 6 with an amino acid substitution at Asn28 or an amino acid substitution at Ser30.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 93.0
- Lexical Diversity: 1.18919
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15348250', '14363514', '15206896', '15434639', '14309403']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.744559311519361
- 35 USC 102 Novelty (BERT): 0.5289491726771679
- Combined Prediction Score: 0.7229982976351417
- Mean Citation Score: 338.825594
- Max Citation Score: 358.24800000000016
- Similarity Product: 322.1448305597306

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test